Eli Lilly’s revenues

Eli Lilly & Co. (LLY) reported 9.0% growth in its YoY (year-over-year) revenues to ~$6.4 billion during the second quarter, compared to $5.8 billion during the second quarter of 2017. Eli Lilly surpassed Wall Street analysts’ EPS and revenue estimates during the second quarter. On July 24, Eli Lilly reported non-GAAP EPS of $1.50 on revenues of ~$6.4 billion, compared to its estimated EPS of $1.30 on revenues of $6.0 billion during the quarter.

In this series, we’ll take a detailed look at Eli Lilly’s second-quarter results. The chart below compares the company’s revenues since the first quarter of 2017.

Eli Lilly: 9% Revenue Growth in Q2 2018 Exceeded Estimates

Q2 2018 performance

Eli Lilly’s (LLY) top line increased 9.0% to ~$6.36 billion during the second quarter, driven by 7.0% volume growth and a 2.0% favorable impact of foreign exchange during the quarter. Eli Lilly’s net adjusted income increased ~33.0% to ~$2.9 billion during the second quarter, compared to the second quarter of 2017.

Geographical performance

The US markets contributed ~50.7% to Eli Lilly’s total revenues during the second quarter. The company’s sales in the US markets reported YoY growth of 11.0% to ~$3.2 billion during the second quarter, compared to the second quarter of 2017.

In the international markets, the company reported YoY growth of 10.0% in sales to ~$2.8 billion during the second quarter, compared to the second quarter of 2017.

Updates for 2018 guidance

Eli Lilly (LLY) updated its financial guidance for 2018. It expects its revenues to reach $24.0 billion–$24.5 billion during 2018, driven by a favorable portfolio and higher collaboration revenues.

The company’s non-GAAP gross profit margin is expected to increase to ~76.0% due to the favorable impact of foreign exchange. Its non-GAAP EPS is expected to reach $5.40–$5.50 for fiscal 2018, compared to its previous guidance of $5.10–$5.20.

The VanEck Vectors Morningstar Wide Moat ETF (MOAT) holds 2.9% of its total investments in Eli Lilly (LLY), 2.8% in Biogen (BIIB), 2.7% in Allergan (AGN), and 2.7% in Merck & Co. (MRK).

Latest articles

According to Reuters, Netflix CEO Reed Hastings (NFLX) said companies like Disney (DIS) and Apple (AAPL) will boost already rising production costs.

President Trump is not happy with the present Fed rate cut. He wants the cutback to be higher. So high that the interest rates are negative.

Yesterday, Goldman Sachs' strategist warned of high volatility in October. Based on Goldman Sachs' data, since 1928 volatility in October is 25% higher.

On September 19, at Delivering Alpha Conference, Jim Chanos said Grubhub (GRUB) is a very good short. He said that Guruhub is almost not making any money.

The Chinese delegation canceled planned goodwill visits to US farms because of trade war escalations. This affected markets yesterday.

Tesla (TSLA) CEO Elon Musk is one of the most widely followed billionaires on Twitter. His love for Twitter is no secret.